Basilea announces approval of antifungal Cresemba (isavuconazole) for invasive aspergillosis in China

Basilea Pharmaceutica

13 January 2022 - Second approved indication after invasive mucormycosis in December 2021.

Basilea Pharmaceutica announced today that its license partner, Pfizer has received a drug approval license from the National Medical Products Administration in China, for the oral formulation of its antifungal Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis.

Read Basilea Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , China